During open enrollment, choose San Diego's best health care. Get started.

About Catriona Jamieson, MD, PhD

Catriona Jamieson, MD, PhD, is a board-certified hematologist with broad clinical expertise in caring for patients with hematologic malignancies. As hematology team leader for the Division of Hematology/Oncology at UC San Diego Health Moores Cancer Center, Dr. Jamieson's clinical interests include the treatment of myeloproliferative neoplasms including chronic myeloid leukemia (CML), polycythemia vera (PV), myelofibrosis and essential thrombocythemia. She is also the principal investigator on several clinical trials for the treatment of these and related bone marrow disorders.

As a physician-scientist, Dr. Jamieson completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as a postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford. Together with collaborators, she discovered in 2004 that chronic phase CML is initiated by blood-forming stem cells through expression of the BCR-ABL gene, but that a patient's transition to the blast crisis stage of CML is driven by myeloid progenitors that have been reprogrammed to behave like leukemia stem cells (LSC) through aberrant activation of the gene beta-catenin (Jamieson et al., The New England Journal of Medicine 2004).

In her own laboratory first at Moores Cancer Center, and now also at the Sanford Consortium for Regenerative Medicine, she has expanded this research to include analysis of the events involved in the initiation and progression of a variety of blood cancers. As a principal investigator on several research grants funded by the California Institute for Regenerative Medicine (CIRM), Dr. Jamieson has a deep interest in understanding the mechanisms fueling the development, progression and therapeutic resistance of hematologic malignancies. Her translational research efforts have led to discovery of small molecule therapeutic inhibitors that are now being tested in two Phase 1 clinical trials for two different blood cancers. A successful, recently completed Phase l clinical trial showed promising results for myelofibrosis. The continued aims of her research group focus on developing novel therapeutic strategies for hematological malignancies that will improve the quality of life of people with these disorders, with the goal of developing curative therapies that will obviate therapeutic resistance and disease relapse.

UC San Diego Health Links
For more information see Blood Disorder Care and Cancer Care.

Medical DegreeThe University of British Columbia, Vancouver, BC, CanadaFellowshipStanford University, School of Medicine, Stanford, CAFellowshipStanford University, School of Medicine, Stanford, CAResidencyThe University of British Columbia, Vancouver, BC, Canada
GenderFemale
LanguagesFrenchSpanish
Date Joined Staff2005-09-02
Board Certifications
Hematology
Conditions and Treatments
  • Bone Marrow Transplant and Hematology
  • Bone Marrow Transplantation
  • Chronic Myeloid Leukemia
  • Myeloproliferative Neoplasms
  • Blood Cancer
  • Hematologic Malignancies
Cancer

Is My Insurance Accepted?

We accept most major insurance plans at UC San Diego Health. Find out if your insurance is accepted.

Videos

Meet Catriona Jamieson, MD, PhD: Hematologist

Meet Catriona Jamieson, MD, PhD: Hematologist

News

Health Cancer Man Beach
Cancer Care as Unique as You

Choose UC San Diego Health for truly personalized cancer care at San Diego's only Comprehensive Cancer Center.

Open Payments Program Notification

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.

View Open Payments Data for Dr. Jamieson